1. Home
  2. ALLK

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN CARLOS
Market Cap: 97.4M IPO Year: 2018
Target Price: $1.83 AVG Volume (30 days): 548.5K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.46 EPS Growth: N/A
52 Week Low/High: $0.98 - $5.64 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: